JGC
SAGE

J. Goldman & Co’s Sage Therapeutics SAGE Stock Holding History

J. Goldman & Co’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-176,000
Closed -$8.99M – 399
2016
Q4 		$8.99M Buy
+176,000
New +$8.3M 0.6% 46
2016
Q3 		– Sell
-169,000
Closed -$5.09M – 384
2016
Q2 		$5.09M Buy
+169,000
New +$5.64M 0.27% 94

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

J. Goldman & Co's SAGE Position: Q3 2024 in Review

J. Goldman & Co sold out of Sage Therapeutics (SAGE) in Q3 2024, closing a stake of 116,842 shares — an estimated $1.27M sold.

J. Goldman & Co first reported a position in SAGE in Q1 2016 and held it in 6 quarters. The position peaked at $3.27M in Q1 2016. 175 funds tracked by Wall St. Rank hold SAGE as of Q3 2024.

  • J. Goldman & Co reported no remaining Sage Therapeutics position as of Q3 2024 after selling out during the quarter.
  • J. Goldman & Co sold 116,842 Sage Therapeutics shares in Q3 2024, an estimated $1.27M.
  • J. Goldman & Co first reported a position in Sage Therapeutics in Q1 2016 and held it in 6 quarters.
  • J. Goldman & Co's Sage Therapeutics position peaked at $3.27M in Q1 2016.
  • 175 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2024.

Based on J. Goldman & Co's 13F filing for Q3 2024, filed 14 Nov 2024.